PT - JOURNAL ARTICLE AU - ANNA ANSCHLAG AU - BRANDON H. GREENE AU - LORIANNA KÖNNEKER AU - MARKUS LUSTER AU - JAMES NAGARAJAH AU - SABINE WÄCHTER AU - ANNETTE WUNDERLICH AU - ANDREAS PFESTROFF TI - Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells <em>In Vitro</em> AID - 10.21873/invivo.12313 DP - 2021 Mar 01 TA - In Vivo PG - 721--729 VI - 35 IP - 2 4099 - http://iv.iiarjournals.org/content/35/2/721.short 4100 - http://iv.iiarjournals.org/content/35/2/721.full SO - In Vivo2021 Mar 01; 35 AB - Background/Aim: We evaluated the potential of the kinase inhibitors sorafenib, lenvatinib and selumetinib on increasing the uptake of technetium-99m into thyroid cancer cells. Materials and Methods: Four established cell lines and three patient’s cell cultures were treated with 0.1, 1 and 5 μM of sorafenib, lenvatinib and selumetinib for 72 hours. After incubation with 1 MBq of technetium-99m, the radioactivity uptake was measured. Results: The experiments showed heterogeneous results. Maximum technetium-99m uptake increases of 312% (sorafenib), 326% (lenvatinib) and 759% (selumetinib) were obtained using the highest applied concentrations. In some tests, an uptake reduction or no effect was observed. Conclusion: Kinase inhibitors have a positive effect on technetium-99m uptake. Due to study limitations, a redifferentiating effect of the drugs could not be definitely proven. Unspecific cytotoxicity might have a confounding effect.